Effects of Inhalation Exposures to an M1-Receptor Agonist on Ventilation in Rhesus Monkeys

ABSTRACT Information was needed on effects of possible occupational inhalation exposure to an M]-receptor agonist (xanomeline) such as might occur during the manufacturing process. Both acute and repeated inhalation exposures to xanomeline were carried out in six male rhesus monkeys using a head-dom...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug and chemical toxicology (New York, N.Y. 1978) N.Y. 1978), 1999, Vol.22 (4), p.595-611
Hauptverfasser: Allen, Darrel L., Leiter, Paula A., Tielking, Richard L., Hoffman, Wherly P., Vidyashankar, Anand N., van Lier, Robert B. L., Wolff, Ronald K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 611
container_issue 4
container_start_page 595
container_title Drug and chemical toxicology (New York, N.Y. 1978)
container_volume 22
creator Allen, Darrel L.
Leiter, Paula A.
Tielking, Richard L.
Hoffman, Wherly P.
Vidyashankar, Anand N.
van Lier, Robert B. L.
Wolff, Ronald K.
description ABSTRACT Information was needed on effects of possible occupational inhalation exposure to an M]-receptor agonist (xanomeline) such as might occur during the manufacturing process. Both acute and repeated inhalation exposures to xanomeline were carried out in six male rhesus monkeys using a head-dome exposure system. Exposure concentrations ranged from 0.3 to 10 mg/m3. The exposure durations were up to 2 weeks. Decreases in tidal volume and increases in respiratory frequency were both time and concentration related during acute exposures. These effects were blocked with atropine pre-treatment. Correlation with pulmonary resistance measurements in two monkeys suggested that these were bronchoconstrictive changes that increased with severity with time at a given concentration and with concentration when measured after a constant exposure time. The dose-response was relatively steep with 10 mg/m3 becoming intolerable to the monkeys after approximately 15 minutes, but no measurable effects were observed at 0.3 mg/m3 after up to 4 hours of exposure. To investigate the effects of repeated exposures, monkeys were exposed for 4 hr/day, 5 days/wk for 2 weeks to 0.0 (air only), 0.3, and 1.2 mg xanomeline/m3 of air. When compared to the air-only exposure, 0.3 mg/m3 caused no significant changes in tidal volume. in contrast, 1.2 mg/m3 caused a rapid and significant decrease in tidal volume that was sustained throughout the 4-hr exposure. A slower rise in breathing frequency also occurred. Repeated exposures did not alter the effects seen after a single exposure. It is concluded that xanomeline, a M1 - receptor agonist, can acutely alter normal ventilation in non-human primates at airborne concentrations ≥0.6 mg/m3 and should be carefully controlled in a manufacturing environment. The no-observed-effect concentration was 0.3 mg/m3.
doi_str_mv 10.3109/01480549908993170
format Article
fullrecord <record><control><sourceid>informahealthcare_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_1179799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_01480549908993170</sourcerecordid><originalsourceid>FETCH-LOGICAL-i256t-4b4459699fe197f3eddb639aeec40ecb738886d3286eaa50e3d8d423a453f193</originalsourceid><addsrcrecordid>eNp1kM9LwzAUx4Mobk7_AC-Sg9dq0jRtg17GmD9gQxjDg5eSti-2s0tKkqL77-3Yhoh4eLzD-3y-8L4IXVJywygRt4RGKeGRECQVgtGEHKEh5SEP4v5yjIbbe9ADfIDOnFsRQkPB2SkaUMJZnHA6RG9TpaDwDhuFn3UlG-lro_H0qzWus-CwN1hqPKfBAgpovbF4_G507TzusVfQvt4rtcaLClzn8NzoD9i4c3SiZOPgYr9HaPkwXU6egtnL4_NkPAvqkMc-iPIo4iIWQgEViWJQlnnMhAQoIgJFnrA0TeOShWkMUnICrEzLKGQy4kxRwUboahfbdvkayqy19VraTXb4sQeu94B0hWyUlbqo3Q9HE5GIbc79Dqu1MnYtP41tyszLTWPswelb347I_jTf63e_9Apk46tCWshWprO6byD73_4GwlCGPA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effects of Inhalation Exposures to an M1-Receptor Agonist on Ventilation in Rhesus Monkeys</title><source>MEDLINE</source><source>Taylor &amp; Francis:Master (3349 titles)</source><source>Taylor &amp; Francis Medical Library - CRKN</source><creator>Allen, Darrel L. ; Leiter, Paula A. ; Tielking, Richard L. ; Hoffman, Wherly P. ; Vidyashankar, Anand N. ; van Lier, Robert B. L. ; Wolff, Ronald K.</creator><creatorcontrib>Allen, Darrel L. ; Leiter, Paula A. ; Tielking, Richard L. ; Hoffman, Wherly P. ; Vidyashankar, Anand N. ; van Lier, Robert B. L. ; Wolff, Ronald K.</creatorcontrib><description>ABSTRACT Information was needed on effects of possible occupational inhalation exposure to an M]-receptor agonist (xanomeline) such as might occur during the manufacturing process. Both acute and repeated inhalation exposures to xanomeline were carried out in six male rhesus monkeys using a head-dome exposure system. Exposure concentrations ranged from 0.3 to 10 mg/m3. The exposure durations were up to 2 weeks. Decreases in tidal volume and increases in respiratory frequency were both time and concentration related during acute exposures. These effects were blocked with atropine pre-treatment. Correlation with pulmonary resistance measurements in two monkeys suggested that these were bronchoconstrictive changes that increased with severity with time at a given concentration and with concentration when measured after a constant exposure time. The dose-response was relatively steep with 10 mg/m3 becoming intolerable to the monkeys after approximately 15 minutes, but no measurable effects were observed at 0.3 mg/m3 after up to 4 hours of exposure. To investigate the effects of repeated exposures, monkeys were exposed for 4 hr/day, 5 days/wk for 2 weeks to 0.0 (air only), 0.3, and 1.2 mg xanomeline/m3 of air. When compared to the air-only exposure, 0.3 mg/m3 caused no significant changes in tidal volume. in contrast, 1.2 mg/m3 caused a rapid and significant decrease in tidal volume that was sustained throughout the 4-hr exposure. A slower rise in breathing frequency also occurred. Repeated exposures did not alter the effects seen after a single exposure. It is concluded that xanomeline, a M1 - receptor agonist, can acutely alter normal ventilation in non-human primates at airborne concentrations ≥0.6 mg/m3 and should be carefully controlled in a manufacturing environment. The no-observed-effect concentration was 0.3 mg/m3.</description><identifier>ISSN: 0148-0545</identifier><identifier>EISSN: 1525-6014</identifier><identifier>DOI: 10.3109/01480549908993170</identifier><identifier>PMID: 10536751</identifier><language>eng</language><publisher>New York, NY: Informa UK Ltd</publisher><subject>Administration, Inhalation ; Airway Resistance - drug effects ; Animals ; Atmosphere Exposure Chambers ; Atropine - pharmacology ; Biological and medical sciences ; Bronchoconstriction ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug toxicity and drugs side effects treatment ; Macaca mulatta ; Male ; Medical sciences ; Muscarinic Agonists - administration &amp; dosage ; Muscarinic Agonists - toxicity ; Pharmacology. Drug treatments ; Pulmonary Ventilation - drug effects ; Pulmonary Ventilation - physiology ; Pyridines - administration &amp; dosage ; Pyridines - toxicity ; Respiration - drug effects ; Thiadiazoles - administration &amp; dosage ; Thiadiazoles - toxicity ; Tidal Volume - drug effects ; Toxicity: respiratory system, ent, stomatology</subject><ispartof>Drug and chemical toxicology (New York, N.Y. 1978), 1999, Vol.22 (4), p.595-611</ispartof><rights>1999 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1999</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/01480549908993170$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/01480549908993170$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1179799$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10536751$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Allen, Darrel L.</creatorcontrib><creatorcontrib>Leiter, Paula A.</creatorcontrib><creatorcontrib>Tielking, Richard L.</creatorcontrib><creatorcontrib>Hoffman, Wherly P.</creatorcontrib><creatorcontrib>Vidyashankar, Anand N.</creatorcontrib><creatorcontrib>van Lier, Robert B. L.</creatorcontrib><creatorcontrib>Wolff, Ronald K.</creatorcontrib><title>Effects of Inhalation Exposures to an M1-Receptor Agonist on Ventilation in Rhesus Monkeys</title><title>Drug and chemical toxicology (New York, N.Y. 1978)</title><addtitle>Drug Chem Toxicol</addtitle><description>ABSTRACT Information was needed on effects of possible occupational inhalation exposure to an M]-receptor agonist (xanomeline) such as might occur during the manufacturing process. Both acute and repeated inhalation exposures to xanomeline were carried out in six male rhesus monkeys using a head-dome exposure system. Exposure concentrations ranged from 0.3 to 10 mg/m3. The exposure durations were up to 2 weeks. Decreases in tidal volume and increases in respiratory frequency were both time and concentration related during acute exposures. These effects were blocked with atropine pre-treatment. Correlation with pulmonary resistance measurements in two monkeys suggested that these were bronchoconstrictive changes that increased with severity with time at a given concentration and with concentration when measured after a constant exposure time. The dose-response was relatively steep with 10 mg/m3 becoming intolerable to the monkeys after approximately 15 minutes, but no measurable effects were observed at 0.3 mg/m3 after up to 4 hours of exposure. To investigate the effects of repeated exposures, monkeys were exposed for 4 hr/day, 5 days/wk for 2 weeks to 0.0 (air only), 0.3, and 1.2 mg xanomeline/m3 of air. When compared to the air-only exposure, 0.3 mg/m3 caused no significant changes in tidal volume. in contrast, 1.2 mg/m3 caused a rapid and significant decrease in tidal volume that was sustained throughout the 4-hr exposure. A slower rise in breathing frequency also occurred. Repeated exposures did not alter the effects seen after a single exposure. It is concluded that xanomeline, a M1 - receptor agonist, can acutely alter normal ventilation in non-human primates at airborne concentrations ≥0.6 mg/m3 and should be carefully controlled in a manufacturing environment. The no-observed-effect concentration was 0.3 mg/m3.</description><subject>Administration, Inhalation</subject><subject>Airway Resistance - drug effects</subject><subject>Animals</subject><subject>Atmosphere Exposure Chambers</subject><subject>Atropine - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Bronchoconstriction</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Macaca mulatta</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Muscarinic Agonists - administration &amp; dosage</subject><subject>Muscarinic Agonists - toxicity</subject><subject>Pharmacology. Drug treatments</subject><subject>Pulmonary Ventilation - drug effects</subject><subject>Pulmonary Ventilation - physiology</subject><subject>Pyridines - administration &amp; dosage</subject><subject>Pyridines - toxicity</subject><subject>Respiration - drug effects</subject><subject>Thiadiazoles - administration &amp; dosage</subject><subject>Thiadiazoles - toxicity</subject><subject>Tidal Volume - drug effects</subject><subject>Toxicity: respiratory system, ent, stomatology</subject><issn>0148-0545</issn><issn>1525-6014</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM9LwzAUx4Mobk7_AC-Sg9dq0jRtg17GmD9gQxjDg5eSti-2s0tKkqL77-3Yhoh4eLzD-3y-8L4IXVJywygRt4RGKeGRECQVgtGEHKEh5SEP4v5yjIbbe9ADfIDOnFsRQkPB2SkaUMJZnHA6RG9TpaDwDhuFn3UlG-lro_H0qzWus-CwN1hqPKfBAgpovbF4_G507TzusVfQvt4rtcaLClzn8NzoD9i4c3SiZOPgYr9HaPkwXU6egtnL4_NkPAvqkMc-iPIo4iIWQgEViWJQlnnMhAQoIgJFnrA0TeOShWkMUnICrEzLKGQy4kxRwUboahfbdvkayqy19VraTXb4sQeu94B0hWyUlbqo3Q9HE5GIbc79Dqu1MnYtP41tyszLTWPswelb347I_jTf63e_9Apk46tCWshWprO6byD73_4GwlCGPA</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>Allen, Darrel L.</creator><creator>Leiter, Paula A.</creator><creator>Tielking, Richard L.</creator><creator>Hoffman, Wherly P.</creator><creator>Vidyashankar, Anand N.</creator><creator>van Lier, Robert B. L.</creator><creator>Wolff, Ronald K.</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><general>Informa Healthcare</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>1999</creationdate><title>Effects of Inhalation Exposures to an M1-Receptor Agonist on Ventilation in Rhesus Monkeys</title><author>Allen, Darrel L. ; Leiter, Paula A. ; Tielking, Richard L. ; Hoffman, Wherly P. ; Vidyashankar, Anand N. ; van Lier, Robert B. L. ; Wolff, Ronald K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i256t-4b4459699fe197f3eddb639aeec40ecb738886d3286eaa50e3d8d423a453f193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Administration, Inhalation</topic><topic>Airway Resistance - drug effects</topic><topic>Animals</topic><topic>Atmosphere Exposure Chambers</topic><topic>Atropine - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Bronchoconstriction</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Macaca mulatta</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Muscarinic Agonists - administration &amp; dosage</topic><topic>Muscarinic Agonists - toxicity</topic><topic>Pharmacology. Drug treatments</topic><topic>Pulmonary Ventilation - drug effects</topic><topic>Pulmonary Ventilation - physiology</topic><topic>Pyridines - administration &amp; dosage</topic><topic>Pyridines - toxicity</topic><topic>Respiration - drug effects</topic><topic>Thiadiazoles - administration &amp; dosage</topic><topic>Thiadiazoles - toxicity</topic><topic>Tidal Volume - drug effects</topic><topic>Toxicity: respiratory system, ent, stomatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Allen, Darrel L.</creatorcontrib><creatorcontrib>Leiter, Paula A.</creatorcontrib><creatorcontrib>Tielking, Richard L.</creatorcontrib><creatorcontrib>Hoffman, Wherly P.</creatorcontrib><creatorcontrib>Vidyashankar, Anand N.</creatorcontrib><creatorcontrib>van Lier, Robert B. L.</creatorcontrib><creatorcontrib>Wolff, Ronald K.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Drug and chemical toxicology (New York, N.Y. 1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Allen, Darrel L.</au><au>Leiter, Paula A.</au><au>Tielking, Richard L.</au><au>Hoffman, Wherly P.</au><au>Vidyashankar, Anand N.</au><au>van Lier, Robert B. L.</au><au>Wolff, Ronald K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Inhalation Exposures to an M1-Receptor Agonist on Ventilation in Rhesus Monkeys</atitle><jtitle>Drug and chemical toxicology (New York, N.Y. 1978)</jtitle><addtitle>Drug Chem Toxicol</addtitle><date>1999</date><risdate>1999</risdate><volume>22</volume><issue>4</issue><spage>595</spage><epage>611</epage><pages>595-611</pages><issn>0148-0545</issn><eissn>1525-6014</eissn><abstract>ABSTRACT Information was needed on effects of possible occupational inhalation exposure to an M]-receptor agonist (xanomeline) such as might occur during the manufacturing process. Both acute and repeated inhalation exposures to xanomeline were carried out in six male rhesus monkeys using a head-dome exposure system. Exposure concentrations ranged from 0.3 to 10 mg/m3. The exposure durations were up to 2 weeks. Decreases in tidal volume and increases in respiratory frequency were both time and concentration related during acute exposures. These effects were blocked with atropine pre-treatment. Correlation with pulmonary resistance measurements in two monkeys suggested that these were bronchoconstrictive changes that increased with severity with time at a given concentration and with concentration when measured after a constant exposure time. The dose-response was relatively steep with 10 mg/m3 becoming intolerable to the monkeys after approximately 15 minutes, but no measurable effects were observed at 0.3 mg/m3 after up to 4 hours of exposure. To investigate the effects of repeated exposures, monkeys were exposed for 4 hr/day, 5 days/wk for 2 weeks to 0.0 (air only), 0.3, and 1.2 mg xanomeline/m3 of air. When compared to the air-only exposure, 0.3 mg/m3 caused no significant changes in tidal volume. in contrast, 1.2 mg/m3 caused a rapid and significant decrease in tidal volume that was sustained throughout the 4-hr exposure. A slower rise in breathing frequency also occurred. Repeated exposures did not alter the effects seen after a single exposure. It is concluded that xanomeline, a M1 - receptor agonist, can acutely alter normal ventilation in non-human primates at airborne concentrations ≥0.6 mg/m3 and should be carefully controlled in a manufacturing environment. The no-observed-effect concentration was 0.3 mg/m3.</abstract><cop>New York, NY</cop><pub>Informa UK Ltd</pub><pmid>10536751</pmid><doi>10.3109/01480549908993170</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0148-0545
ispartof Drug and chemical toxicology (New York, N.Y. 1978), 1999, Vol.22 (4), p.595-611
issn 0148-0545
1525-6014
language eng
recordid cdi_pascalfrancis_primary_1179799
source MEDLINE; Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN
subjects Administration, Inhalation
Airway Resistance - drug effects
Animals
Atmosphere Exposure Chambers
Atropine - pharmacology
Biological and medical sciences
Bronchoconstriction
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug toxicity and drugs side effects treatment
Macaca mulatta
Male
Medical sciences
Muscarinic Agonists - administration & dosage
Muscarinic Agonists - toxicity
Pharmacology. Drug treatments
Pulmonary Ventilation - drug effects
Pulmonary Ventilation - physiology
Pyridines - administration & dosage
Pyridines - toxicity
Respiration - drug effects
Thiadiazoles - administration & dosage
Thiadiazoles - toxicity
Tidal Volume - drug effects
Toxicity: respiratory system, ent, stomatology
title Effects of Inhalation Exposures to an M1-Receptor Agonist on Ventilation in Rhesus Monkeys
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T05%3A24%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Inhalation%20Exposures%20to%20an%20M1-Receptor%20Agonist%20on%20Ventilation%20in%20Rhesus%20Monkeys&rft.jtitle=Drug%20and%20chemical%20toxicology%20(New%20York,%20N.Y.%201978)&rft.au=Allen,%20Darrel%20L.&rft.date=1999&rft.volume=22&rft.issue=4&rft.spage=595&rft.epage=611&rft.pages=595-611&rft.issn=0148-0545&rft.eissn=1525-6014&rft_id=info:doi/10.3109/01480549908993170&rft_dat=%3Cinformahealthcare_pasca%3E10_3109_01480549908993170%3C/informahealthcare_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10536751&rfr_iscdi=true